Graves' orbitopathy after allogeneic bone marrow transplantation in a patient with Fanconi anemia - side effect of alemtuzumab therapy?

Luminita Nicoleta Cima; Ioana Maria Lambrescu; Lavinia Stejereanu; Anca Colita; Reuven Or; Simona Fica

doi:10.1002/ccr3.1486

Graves' orbitopathy after allogeneic bone marrow transplantation in a patient with Fanconi anemia - side effect of alemtuzumab therapy?

Clin Case Rep. 2018 Mar 12;6(5):867-870. doi: 10.1002/ccr3.1486. eCollection 2018 May.

Authors

Luminita Nicoleta Cima¹, Ioana Maria Lambrescu^{1

2}, Lavinia Stejereanu^{1

2}, Anca Colita^{3

4}, Reuven Or^{5

6}, Simona Fica^{1

7}

Affiliations

¹ Endocrinology Carol Davila University of Medicine and Pharmacy Bucharest Romania.
² Carol Davila University of Medicine and Pharmacy Bucharest Romania.
³ Department of Pediatric Bone Marrow Transplantation Fundeni Hospital Bucharest Romania.
⁴ Pediatrics Carol Davila University of Medicine and Pharmacy Bucharest Romania.
⁵ Department of Bone Marrow Transplantation Cancer Immunotherapy & Immunobiology Research Center Hadassah University Hospital Jerusalem Israel.
⁶ Hematology Hadassah Hebrew University Medical Center Jerusalem Israel.
⁷ Department of Endocrinology, Diabetes and Metabolic Disorders Elias University Hospital Bucharest Romania.

Abstract

A few cases of thyroid eye disease following alemtuzumab therapy have been described in patients with multiple sclerosis. Our patient is the first case of Graves' orbitopathy after alemtuzumab conditioning for hematopoietic stem cell transplantation.

Keywords: Graves’ orbitopathy; alemtuzumab therapy; bone marrow transplantation.

Publication types

Case Reports